Fusion Antibodies (LSE:FAB) Debt-to-Revenue : 0.04 (As of Sep. 2023)

Fusion Antibodies Debt-to-Revenue Chart

Fusion Antibodies Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23
Debt-to-Revenue		Get a 7-Day Free Trial				0.06	0.10	0.06	0.01	0.03

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Revenue	Get a 7-Day Free Trial											0.03	0.02	0.09	0.04	0.04

Competitive Comparison of Fusion Antibodies's Debt-to-Revenue

For the Biotechnology subindustry, Fusion Antibodies's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Antibodies's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Debt-to-Revenue falls into.

Fusion Antibodies Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Fusion Antibodies's Debt-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Fusion Antibodies's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Sep. 2023) Revenue data.

Fusion Antibodies Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description